DEEP RESEARCH · IMBiologics

IMBiologics: A Dark-Horse Korean IPO with a Validated RIPCO Model and OX40L Bispecific Platform

Next-gen bispecific antibody platform in autoimmune disease, and the KOSDAQ IPO diagnosis

Date: 2026-02-28 · Biotech fundamentals / IPO / sector strategy · Naver blog original

0. Bottom line first

1. Company overview and business model

1.1. RIPCO (Research Intensive Pharmaceutical Company) strategy

Founded August 2020 as an innovative antibody drug developer. The model rigorously follows RIPCO — unlike FIPCO that runs the full drug-development life cycle in-house, IMBiologics concentrates R&D on discovery and early clinical (Phase 1 / Phase 2 PoC) and out-licenses to global big pharma or specialized clinical developers at the optimal moment.

Official fact: The company packaged its flagship pipelines 'IMB-101 (bispecific)' and 'IMB-102 (monoclonal)' and achieved early global tech-out in 2024, just four years after founding.

1.2. Three-year cash flow and runway

Official fact: 2024 tech-outs with Navigator Medicines (US) + Huadong Pharmaceutical (China) produced revenue of KRW 27.594bn and operating profit of KRW 13.998bn. 3Q25 cumulative reverted to cash burn (revenue 1.282bn, op loss 5.556bn).

Official fact: November 2025 single-month revenue KRW 10.337bn, op profit KRW 7.708bn — result of terminating Huadong's Asia contract and consolidating Asia rights into Navigator (extra upfront ~USD 1.5M).

Interpretation: This lumpy cash flow is the strongest financial moat against the chronic risk of money-losing biotechs — shareholder dilution from CB/rights offerings. Hundreds of billions of KRW in upfronts across 2024 + 2H25 extended the runway through IMB-101 global Phase 2 PoC (~2028). Combined with KRW 38–52bn IPO proceeds, this completes a balance sheet that can ignore external capital-market volatility for 3–4 years.

1.3. Customers (big pharma · NewCo structure)

The actual 'customer' is not patients but global big pharma and specialized clinical biotechs. Lead partner Navigator Medicines (US) is a NewCo-type special-purpose biotech that raised USD 100M+ in Series A — capital and US clinical expertise both in place.

Interpretation: NewCo partnerships move faster than direct big-pharma deals. If Navigator secures PoC in Phase 2, sub-licensing or M&A by J&J, AbbVie, or Sanofi follows, and IMBiologics receives a share as originator — the real trigger for future enterprise value.

1.4. Technological moat — IM-OpDECon platform

The OX40L + TNF-α bispecific mechanism in IMB-101 is a step beyond first-generation autoimmune therapies. Single TNF-α blockers like AbbVie's Humira suppress inflammation strongly but risk tolerance, immunosuppression, and lethal opportunistic infections with long-term dosing. IMB-101 simultaneously blocks TNF-α for rapid inflammation control and targets the upstream immune modulator OX40L without killing T cells — selectively normalizing the overactive immune response. Genuinely best-/first-in-class.

2. Company history and key people

2.1. Milestones

• Aug 2020 — Incorporation.
• Nov 2020 — Licensed in OXTIMA exclusive development rights from HK inno.N.
• Jun 2024 — Global (ex-Asia) tech-out of IMB-101/102 to Navigator Medicines (total USD 944.75M).
• Aug 2024 — Asia rights tech-out to Huadong Pharmaceutical.
• Oct 2025 — Huadong contract terminated; Asia rights consolidated into Navigator (additional ~USD 317.25M).
• Mar 2026 (planned) — KOSDAQ technology-special listing. NICE Information Service + Korea Technology Finance Corp. both rated 'A'.

2.2. Verified management track record

• Ha Kyung-sik, CEO — Former oncology clinical lead, bio BD lead, bio research center director at CJ CheilJedang / CJ Healthcare (now HK inno.N); led 4+ tech-outs.
• Lee Jung-min, CTO/Lab head — PhD Yonsei bioengineering; former CJ Healthcare new-drug group lead. 34+ patents, 8 INDs.
• Park Ji-hye, CDO/Development head — KAIST PhD, Harvard Medical postdoc, licensed pharmacist; former HK inno.N clinical center head. Global regulatory specialist.
• Hong Ji-yeon, BD group lead — Former Daewoong Pharma autoimmune team open collaboration leader.

Official fact: IMB-101 received FDA Phase 1 IND approval just one month after submission with no deficiency letters — regulatory affairs and protocol design are top-tier global standard.

3. Investment history and capital structure

3.1. Pre-IPO funding

Official fact: Cumulative KRW 37bn+ raised through Seed–Series B. Total 5,663,025 RCPS/CPS issued; refixing applied on 6 Aug 2025 and the full block converted into 6,463,218 common shares.

Interpretation: Under K-IFRS, RCPS is classified as liability not equity, creating an accounting mirage where derivative-liability balloons as the company's valuation rises. As of year-end 2024, embedded derivative liabilities were KRW 99.1bn, producing apparent full capital impairment (−KRW 77.2bn). The common-share conversion eliminated this in one stroke — debt-to-equity ratio normalized to a healthy 21.1%. The post-IPO balance sheet is clean, with intrinsic value translating directly into share price.

3.2. VC and SI network

• FI: Atinum Investment, KB Investment, Shinhan Venture Investment — top-tier houses.
• SI: Joint research with Dong-A ST on IMB-104. Selected for J&J's JLABS Korea.

4. Shareholders and overhang risk

4.1. Post-IPO structure

Official fact: 2M new shares offered; total post-offering shares ~14.73M (existing 12.73M + new 2M). Founder & related parties hold ~18.55%. Founder and core related parties pledged self-imposed lock-up of up to 3 years — exceeding KOSDAQ requirements.

4.2. VC exit-behavior analysis

Core FI post-IPO stakes: Atinum Growth Investment Fund 2020 ~8.79%, KB Smart Scale-up Fund ~5.73%, Shinhan Venture Tomorrow Fund 1 ~4.88%. Core FIs voluntarily committed to 1–3+ month lock-ups for staged disposals.

Interpretation: Atinum has a long-tail exit track record (held G2GBio from KRW 300bn cap through KRW 1tn cap). Large funds with weak maturity pressure are likely to hold through fundamental catalysts like Phase 2 entry (1Q26 expected) or Sub-L/O.

Official fact: Indicative band KRW 19,000–26,000; band-low market cap ~KRW 280bn — extremely low against the KRW 1.8tn cumulative tech-out track record.

5. Competitive landscape — autoimmune disease

Official fact: Autoimmune market: 2025 ~USD 231.2bn → 2032 ~USD 396.3bn (~KRW 550tn), CAGR 8.0%.

5.1. Hidradenitis suppurativa (HS) — HiSCR75 comparison

Interpretation: Sanofi's brivekimig uses a llama/alpaca-derived nanobody construct — latent ADA / immunogenicity risk. IMB-101 is a human IgG-based 'dumbbell' bispecific — body-friendly, low immunogenicity, long half-life. That's IMB-101's decisive clinical and commercial edge within the same mechanism.

5.2. Atopic dermatitis (AD) — IMB-102 vs Sanofi's amlitelimab

Sanofi's Dupixent dominates the AD market. Sanofi pushed amlitelimab as the next-gen OX40L blocker in Phase 3 (COAST 1, 2). Recent data was mixed — US co-primary met, EU co-primary missed. Sanofi still plans 2H26 FDA filing on the strength of Q12W dosing convenience.

Official fact: In preclinical mouse models at equivalent doses, IMB-102 reduced ear thickness by 30.9% vs 12.5% for amlitelimab — 2x+ stronger.

Interpretation: An amlitelimab FDA approval would open a regulatory pathway for the OX40L mechanism worldwide, de-risking follower IMB-102. Meanwhile amlitelimab's EU miss exposes efficacy vulnerability — IMB-102 has real room to take share as Best-in-Class.

6. Use of IPO proceeds and risks

6.1. Use of proceeds

Official fact: Proceeds KRW 38–52bn. R&D spend over the next 3 years (2026–2028) totals KRW 60bn+ (KRW 18.9bn in 2026, KRW 24.9bn in 2027, KRW 14.5bn in 2028).

• IMB-101 / IMB-102: Global clinical costs borne by Navigator. Phase 2 entry virtually certain in 1Q26; 2028 PoC → big-pharma Sub-L/O jackpot.
• IMB-106: Signing of joint R&D / licensing option main contract with a US biotech in 2026; 2028 US FDA IND.
• IMB-201 (HLA-G ADC): ~KRW 17.8bn invested, targeting Phase 1 entry + Sub-L/O in 2028.
• IMB-402 (glioblastoma IgM multimer): ~KRW 9.9bn invested, targeting 2028 IND.

6.2. Key risks

1. VC lock-up expiry overhang — Without a price-defending catalyst at the 1–3 month voluntary lock-up expiry (~mid-2026), large profit-taking pressure.
2. Single-partner concentration — 90%+ of next 3 years' projected revenue depends on Navigator Medicines. Navigator funding stress, or toxicity/AE findings in Phase 1b/2 forcing return of rights, would deliver a potentially unrecoverable blow. Accelerating IMB-201 (ADC) partnership is the structural mitigation.

7. Macro and sector top-pick diagnosis

7.1. Three megatrends (2026–2028)

1. US Biosecure Act — Restrictions on Chinese players like WuXi AppTec raise the bar for Korean CDMOs and R&D-specialty biotechs.
2. Global rate-cut cycle — Suppressed biotech valuations rebound; big-pharma L/I demand surges → RIPCO model direct beneficiary.
3. 2028 patent cliff (Keytruda, Opdivo, Dupixent) → 2028–2033 KRW ~126tn market exposure. Big pharma is betting the house on bispecifics and ADC platforms.

7.2. Sector top picks

7.3. Portfolio strategy

• Core — Anchor with Alteogen and LigaChem Bio to harvest megatrends safely.
• Alpha — Use the post-IPO VC lock-up expiry volatility to buy below band-low (KRW 19,000 / ~KRW 280bn cap). Aim at the 2H26 global Phase 2 entry momentum and the 2028 potential Sub-L/O jackpot.